title: AIDS-related non-Hodgkin lymphoma: final analysis of 485 patients treated with risk-adapted intensive chemotherapy.
abstract: We aimed to compare AIDS risk-adapted intensive chemotherapy in AIDS-related lymphoma (ARL) patients before and after the advent of highly active antiretroviral therapy (HAART). A total of 485 patients aged from 18 to 67 years were randomly assigned to chemotherapy after stratification according to an HIV score based on performance status, prior AIDS, and CD4(+) cell counts below 0.10 x 10(9)/L (100/mm(3)). A total of 218 good-risk patients (HIV score 0) received ACVBP (doxorubicin, cyclophosphamide, vindesine, bleomycin, and prednisolone) or CHOP (doxorubicin, cyclophosphamide, vincristine, and prednisolone); 177 intermediate-risk patients (HIV score 1), CHOP or low-dose CHOP (Ld-CHOP); and 90 poor-risk patients (HIV score 2-3), Ld-CHOP or VS (vincristine and steroid). The 5-year overall survival (OS) in the good-risk group was 51% for ACVBP versus 47% for CHOP (P = .85); in the intermediate-risk group, 28% for CHOP versus 24% for Ld-CHOP (P = .19); and in the poor-risk group, 11% for Ld-CHOP versus 3% for VS (P = .14). The time-dependent Cox model demonstrated that the only significant factors for OS were HAART (relative risk [RR] 1.6, P < .001), HIV score (RR 1.7, P < .001), and the International Prognostic Index (IPI) score (RR 1.5, P < .001) but not chemotherapy regimen. Our findings indicate that in ARL patients, HIV score, IPI score, and HAART affect survival but not the intensity of the CHOP-based chemotherapy.
authors.affiliation: Institut Universitaire d'Hématologie-GELA, INSERM U728-Hôpital Saint Louis-AP-HP-1, Avenue Claude Vellefaux, 75010 Paris, France. nicolas.mounier@sls.ap-hop-paris.fr
authors.forename: Nicolas
authors.initials: N
authors.lastname: Mounier
authors.forename: Michele
authors.initials: M
authors.lastname: Spina
authors.forename: Jean
authors.initials: J
authors.lastname: Gabarre
authors.forename: Martine
authors.initials: M
authors.lastname: Raphael
authors.forename: Giuliano
authors.initials: G
authors.lastname: Rizzardini
authors.forename: Jean-Baptiste
authors.initials: JB
authors.lastname: Golfier
authors.forename: Emanuela
authors.initials: E
authors.lastname: Vaccher
authors.forename: Antonino
authors.initials: A
authors.lastname: Carbone
authors.forename: Bertrand
authors.initials: B
authors.lastname: Coiffier
authors.forename: Guido
authors.initials: G
authors.lastname: Chichino
authors.forename: Andre
authors.initials: A
authors.lastname: Bosly
authors.forename: Umberto
authors.initials: U
authors.lastname: Tirelli
authors.forename: Christian
authors.initials: C
authors.lastname: Gisselbrecht
mesh_terms: D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000627:therapeutic use*; D023241:Antiretroviral Therapy, Highly Active; D018791:CD4 Lymphocyte Count; D003520:Cyclophosphamide / Q000008:administration & dosage; D004317:Doxorubicin / Q000008:administration & dosage; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D016483:Lymphoma, AIDS-Related / Q000145:classification / Q000188:drug therapy* / Q000401:mortality; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D011239:Prednisolone / Q000008:administration & dosage; D018570:Risk Assessment; D016019:Survival Analysis; D014750:Vincristine / Q000008:administration & dosage
chemical_list: D014750:Vincristine; D004317:Doxorubicin; D003520:Cyclophosphamide; D011239:Prednisolone